Skip to main content
. 2019 Apr 20;6(12):1900386. doi: 10.1002/advs.201900386

Figure 4.

Figure 4

a) Real‐time PCR analysis for Cas9 mRNA expression in VSMCs treated as indicated. b,c) Western blot analysis of Cas9 protein expression in VSMCs incubated with nanoparticles with an anti‐Flag antibody. d) Sanger sequencing of PCR amplicon of the targeted Fbn1 locus in CHO‐PGEA/pCas9‐sgFbn1 treated VSMCs. e) Western blot analysis of Fbn1 induced phosphorylation of Smad2/3 (p‐Smad2/3) in VSMCs after treatment with CHO‐PGEA/pCas9‐sgFbn1 or CHO‐PGEA/pCas9‐sgnull. f) The mRNA levels of Fbn1 targeted genes Mmp‐2 and Ctgf in VSMCs after the treatments with CHO‐PGEA/pCas9‐sgFbn1 and CHO‐PGEA/pCas9‐sgnull. *P < 0.05, **P < 0.01, and ***P < 0.001.